BioXpedia A/S’ Post

Get your self a Christmas present with an exclusive 3-day pass to the Proteomics Based Drug Discovery Summit (February 11-13, 2025) in Boston – and save $500 when you book before December 20! With 19+ expert speakers, 17+ sessions all with new data, and 6 hours of hands-on workshops, this is the event for anyone tackling challenges like: Lack of sensitive or high-throughput mass spectrometry, difficulty elucidating drug mechanisms of action, noisy proximity labelling data or hard to parse biomarker analysis. Here’s a sneak peek at just a few of the unmissable sessions: Deconvolute Protein Complexes to Understand the Mechanism of Action for Small Molecule Drugs with Rhushikesh Kulkarni, Principal Scientist at Pfizer Enable Drug Target Identification & Ligandable Residue Mapping with Francisco Garcia, Principal Scientist at Novartis Characterize the Selectivity & Target Engagement of CNS-Penetrant Degraders for Multiple Sclerosis with Bekim Bajrami, Associate Scientific Director at Biogen 🎁 Don’t miss out – book your pass now and unwrap the gift of knowledge this holiday season. Join 50+ proteomics experts to discover actionable strategies and the latest data to accelerate small molecule drug discovery. 👉 Download the brochure: https://ter.li/k67c1t 👉 Book your pass: https://ter.li/k67c1ti #proteomics #chemoproteomics #massspectrometry #drugdiscovery #proximitylabelling #biomarkeranalysis #setsa #ligandmapping #mechanismofaction #MoA #highthroughputscreening

Our recent publication in collaboration with X-Chem, Inc., Relay Therapeutics, and Google, showcases a large-scale approach to discovering and characterizing small-molecule ligands for the WD40 repeat (WDR) protein family-a promising but underexplored target class with over 350 members in the human genome. Through cloning, expressing, and purifying 100 distinct WD40 proteins, we established a comprehensive resource of protocols for protein production, structural characterization, and biochemical and cellular assays. Our pilot screen, leveraging DNA-encoded libraries and machine learning predictions, successfully identified first-in-class, drug-like ligands for 7 out of 16 screened WDR domains. Tip from the experts: Don’t miss the supplementary information, which includes an extensive dataset and toolkit-an enormous volume of work from SGC researchers that is now publicly available, enabling and empowering researchers worldwide to explore WDR proteins further. Read the full study here: https://lnkd.in/gvuixmsR #DrugDiscovery #OpenScience #WDRproteins

Delighted to share that I have successfully completed my certification course in Drug Discovery from University of California, San Diego!🎓 Throughout this program, I delved into the intricacies of drug development, focusing on essential topics such as proteomics, genomics and the critical process of compound selection. I also explored the vital stages of preclinical studies and the innovative approach of fragment-based drug discovery. A heartfelt thank you to my instructor, Williams Ettouati, for his invaluable insights and support throughout the course. I am eager to apply what I’ve learned and connect with fellow professionals to contribute to advancements in the pharmaceutical field. #DrugDiscovery #Proteomics #Genomics #PharmaceuticalResearch #UCSD

With CHO cell lines having been the predominant host cell line of choice for many years, it’s interesting to see a paper focusing on an alternative host cell line. In this paper, the authors report on the development of a glucose feed control system for a recombinant cell line derived from the Chinese hamster lung (CHL)-YN host cell line. They also compare data from a metabolomics analysis of the CHL-YN cell line with that from a CHO-K1 cell line, revealing differences between the two. Sukwattananipaat, P., Kuroda, H., Yamano-Adachi, N., & Omasa, T. (2024). Metabolomic characterization of monoclonal antibody-producing Chinese hamster lung (CHL)-YN cells in glucose-controlled serum-free fed-batch operation. Biotechnology and Bioengineering, 1–20. #celllinedevelopment #cho #cellculture #bioprocessing #biopharmaceuticals #metabolomics https://lnkd.in/eWjHQwvd

SDBN Feed: Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators https://lnkd.in/dpsYTw8y SAN DIEGO–(BUSINESS WIRE)– #chemokineassays–Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend its targeted proteomics services to include high-sensitivity cytokine, chemokine, and [...]

I am thrilled to share that our paper, "A Comparison of Branched DNA and Reverse Transcriptase Quantitative Polymerase Chain Reaction Methodologies for Quantitation of Lipid Nanoparticle Encapsulated mRNA", has been published in the Bioanalysis Journal! This work represents a significant step forward in mRNA quantification, particularly highlighting the transition from bDNA to RT-qPCR methodologies for encapsulated mRNA. Our study provides insights that could serve as a blueprint for regulatory agencies and biotechnology companies working on mRNA-based therapeutics. Special thanks to my amazing co-authors and collaborators for their hard work and dedication. #science #biotechnology #research #mRNA #bioanalysis #PCR #pharmacokinetics #publication Read the full paper here: https://lnkd.in/gtXBQmp3

We're proud to announce that our researchers from the Olsen lab have published groundbreaking work in Nature Communications, introducing a streamlined approach to drug target identification using proteomics. The Olsen team together with several other groups at CPR have developed an optimized label-free quantitative proteomics method that enhances the traditional TPP/TPP-PISA approach, making it more efficient and comprehensive in identifying drug-protein interactions. This advancement allows for faster, more scalable screening of potential drug targets across entire proteomes. Using rat organ extracts ex-vivo, their research revealed organ-specific drug interactions and uncovered new targets for common medications, including Ibuprofen. These findings have important implications for drug development and repurposing. Read more in Nature Communications: https://lnkd.in/dJ6wFYqn #DrugDiscovery #Proteomics #Research #Science

LOST IN TRANSLATION 🧬—Where Omics meets Drug Discovery. Join Stefan Ledinger, Markus Langsdorf, Bruno Manadas & Dorte Breinholdt Bekker-Jensen as they discuss how OMICS sciences are revolutionizing drug discovery in the pharmaceutical industry. 📅 May 16th ⏰ Time: 10-12 AM CET Topics include industrialized omics, biomarker discovery, quantitation, metabolomics, and lipidomics using various SCIEX technologies and solutions. Don't miss this opportunity to gain insights into the cutting-edge advancements shaping the future of pharmaceutical research and development. 🌐 Register now: https://shorturl.at/emyMT #Webinar #Omics #Pharma #Metabolomics

🔬Expanding our toolbox to deal with disease related proteins A recent preprint by Kheewoong Baek et al. provides a comprehensive blueprint for robust and scalable identification of drug-induced protein degradation. This paves the way for novel therapeutic strategies through targeted protein degradation. Mass spectrometry-based targeted protein degradation is revolutionizing drug discovery by expanding the druggable proteome as it allows for identification of compounds that degrade disease-causing proteins. With this approach researchers can develop strategies to deal with previously undruggable targets, opening new avenues for treatment and enhancing the efficacy of existing therapies. Thanks to the teams around Eric Fischer, Katherine Donovan, Nathanael Gray for this amazing research! https://lnkd.in/g8_AiNuV #TPD #Chemoproteomics #DrugDiscovery #ProteinDegradation #MolecularGlues #timsTOF #StayCurious

SDBN Trending News: Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators https://lnkd.in/gkeatew4 SAN DIEGO–(BUSINESS WIRE)– #chemokineassays–Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend its targeted proteomics services to include high-sensitivity cytokine, chemokine, and [...]